NCT04411914View on ClinicalTrials.gov

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

November 23, 2021

Study Completion Date

March 31, 2022

Conditions
Cocaine Dependence
Interventions
DRUG

Clavulanic Acid

Drug will be given in 250mg capsules.

OTHER

Placebo

Placebo

Trial Locations (1)

19125

Temple University Episcopal Hospital, Philadelphia

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Temple University

OTHER

NCT04411914 - Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid | Biotech Hunter | Biotech Hunter